Peptide Formulation Stability¶
Executive Summary¶
Peptide therapeutics occupy a unique position in pharmaceutical development, combining the potency and specificity of biologics with the manufacturing scalability of small molecules. However, their inherent chemical complexity makes them substantially more susceptible to degradation than small-molecule drugs. A comprehensive stability program for peptide formulations must address two fundamental categories: chemical instability (covalent bond alterations) and physical instability (non-covalent conformational and colloidal changes).
Chemical degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine and cysteine, hydrolysis of aspartate-proline and other labile peptide bonds, β-elimination at cysteine residues, and racemization of amino acid stereocenters. Physical degradation manifests as aggregation (soluble and insoluble), precipitation, surface adsorption, and conformational changes. These pathways often interact in complex ways — chemical modifications can trigger physical aggregation, and formulation conditions that suppress one pathway may accelerate another.
The pharmaceutical industry relies on rigorous stability testing frameworks, principally ICH Q1A(R2), to establish shelf-life and recommended storage conditions. Arrhenius kinetic modeling enables prediction of long-term stability from accelerated temperature studies, while forced degradation studies systematically reveal the intrinsic vulnerabilities of each peptide sequence. This article provides a detailed scientific examination of each degradation pathway, the principles of stability-indicating analytical methodology, the application of kinetic modeling, and the regulatory framework governing stability testing for peptide pharmaceuticals.
Background¶
The stability challenges of peptide drugs have been recognized since the earliest therapeutic applications of insulin in the 1920s. Early insulin formulations required refrigeration and exhibited variable potency due to uncontrolled degradation. The development of modern peptide pharmaceuticals — from GnRH agonists like leuprolide to GLP-1 receptor agonists including semaglutide — has been paralleled by advances in understanding degradation mechanisms and developing formulation strategies to mitigate them.
The regulatory framework for stability testing was formalized through the International Council for Harmonisation (ICH) guideline Q1A(R2), "Stability Testing of New Drug Substances and Products," first adopted in 1993 and revised in 2003. This guideline establishes the requirements for long-term (real-time), intermediate, and accelerated stability testing under controlled temperature and humidity conditions. For peptide products, which are typically stored under refrigerated (2–8°C) or frozen (−20°C or below) conditions, the ICH climatic zones provide a standardized framework.
The unique complexity of peptide stability arises from the presence of multiple reactive functional groups within a single molecule. A typical 30-residue peptide may contain asparagine residues susceptible to deamidation, methionine residues vulnerable to oxidation, aspartate-proline bonds prone to hydrolysis, and hydrophobic regions that drive aggregation. Each residue's microenvironment — determined by primary sequence, secondary structure, and formulation conditions — modulates its intrinsic reactivity, creating a complex, multi-dimensional stability landscape.
Chemical Degradation Pathways¶
Deamidation¶
Deamidation is among the most prevalent and well-characterized chemical degradation pathways for peptides and proteins. The reaction primarily affects asparagine (Asn) residues and, to a lesser extent, glutamine (Gln) residues. The mechanism proceeds through a cyclic imide (succinimide for Asn, glutarimide for Gln) intermediate formed by intramolecular nucleophilic attack of the backbone amide nitrogen of the C-terminal adjacent residue (n+1) on the side-chain carbonyl carbon of the asparagine or glutamine.
The succinimide intermediate is chiral-labile and can hydrolyze to yield two products: L-aspartyl (Asp) and D-isoaspartyl (isoAsp) peptides in approximately a 1:3 ratio under physiological conditions. Isoaspartate formation introduces an additional methylene group into the peptide backbone, altering local conformation and potentially abolishing biological activity. The rate of deamidation is strongly influenced by the identity of the n+1 residue: glycine, serine, and asparagine at the n+1 position accelerate deamidation due to minimal steric hindrance, while bulky residues such as isoleucine and valine retard the reaction.
Deamidation rates depend critically on pH, temperature, and buffer composition. The pH-rate profile typically exhibits a minimum between pH 3.0 and 5.0, with rate acceleration at both acidic (direct hydrolysis) and neutral-to-alkaline (succinimide-mediated) pH. Phosphate buffer has been shown to catalyze deamidation compared to other buffer species at equivalent pH, a phenomenon attributed to general base catalysis of the succinimide ring-closure step.
Oxidation¶
Oxidation is a major degradation pathway affecting methionine (Met), cysteine (Cys), tryptophan (Trp), histidine (His), and tyrosine (Tyr) residues. Methionine oxidation to methionine sulfoxide is the most commonly observed oxidative modification in peptide formulations, occurring through reaction with atmospheric oxygen, dissolved oxygen in solution, or peroxide contaminants present in formulation excipients (particularly polysorbates).
Methionine oxidation proceeds through a nucleophilic attack of the thioether sulfur on an electrophilic oxygen species, forming methionine sulfoxide (Met(O)). Further oxidation to methionine sulfone is possible under strongly oxidizing conditions but is less commonly observed in pharmaceutical formulations. The reaction is accelerated by light (photo-oxidation), transition metal ions (especially Fe²⁺/Fe³⁺ and Cu²⁺), and elevated temperature. Methionine residues that are solvent-exposed oxidize more rapidly than those buried in secondary structure, and the sequence context — particularly the proximity of other methionine or aromatic residues — influences oxidation susceptibility.
Cysteine oxidation involves conversion of the free thiol to cysteine sulfinic acid and cysteine sulfonic acid, or disulfide bond scrambling and exchange. Disulfide bond integrity is critical for the conformation and biological activity of disulfide-containing peptides, including oxytocin, vasopressin, and many peptide toxins. β-Elimination from disulfide bonds or cysteine residues generates dehydroalanine, which can further react with lysine or cysteine side chains to form non-native crosslinks.
Tryptophan oxidation products include N-formylkynurenine, kynurenine, and 5-hydroxytryptophan, which are accompanied by characteristic changes in UV absorbance and fluorescence that serve as useful stability-indicating signals.
Peptide Bond Hydrolysis¶
Hydrolysis of peptide bonds represents a non-specific degradation pathway that is accelerated at extreme pH values. However, certain sequences exhibit markedly enhanced susceptibility to hydrolytic cleavage. The Asp-Pro bond is particularly labile under acidic conditions, with hydrolysis rates up to 100-fold greater than typical peptide bonds. This lability arises from the unique cyclic structure of proline, which places strain on the adjacent peptide bond, combined with acid-catalyzed protonation of the aspartyl side-chain carboxyl group that facilitates nucleophilic attack by water.
Asp-Gly, Asp-Ser, and Asp-His bonds also exhibit enhanced hydrolytic lability. The mechanism involves aspartic acid side-chain carboxyl participation analogous to aspartic protease catalysis. Hydrolysis rates increase with temperature and at both extremes of pH, with a minimum typically observed near neutral pH for most peptide bonds, though Asp-Pro hydrolysis is fastest at pH 2–4.
β-Elimination¶
β-Elimination primarily affects cysteine and cystine residues under alkaline conditions. Base abstracts the α-proton of a cysteine residue, leading to elimination of the thiolate or disulfide leaving group and formation of dehydroalanine. The resulting dehydroalanine is an electrophilic species that can undergo Michael addition with nucleophilic side chains (particularly lysine ε-amino groups and cysteine thiols), forming irreversible crosslinks.
This pathway is particularly significant for disulfide-rich peptides formulated at neutral to alkaline pH. The resulting crosslinked species often exhibit altered conformation, reduced biological activity, and increased immunogenicity potential.
Racemization¶
Racemization refers to the inversion of configuration at amino acid α-carbons, converting L-amino acids to the corresponding D-enantiomers. This process occurs through base-catalyzed abstraction of the α-proton, generating a planar carbanion intermediate that can be reprotonated from either face. Racemization is accelerated at alkaline pH, elevated temperature, and in the presence of certain metal ions.
While individual residue racemization may have modest effects on the properties of larger peptides, cumulative racemization can significantly alter conformation, biological activity, and metabolic stability. Aspartic acid and serine residues are particularly susceptible due to the electron-withdrawing effects of their side chains, which stabilize the carbanion intermediate.
Physical Degradation Pathways¶
Aggregation¶
Peptide aggregation is one of the most challenging physical stability problems in formulation development. Aggregation can occur through multiple mechanisms:
Nucleation-dependent aggregation involves a rate-limiting nucleation step followed by rapid aggregate growth. The formation of a critical nucleus (typically an oligomeric species with specific conformational features) is thermodynamically unfavorable, creating a lag phase. Once nuclei are present, monomer addition proceeds rapidly. This mechanism explains the stochastic nature of peptide aggregation and the observation that seeding with pre-formed aggregates dramatically accelerates the process.
Conformational aggregation is driven by partial unfolding or misfolding of the peptide, exposing hydrophobic surface area that drives intermolecular association. Peptides with significant hydrophobic content or amphipathic character are particularly prone to this pathway. The resulting aggregates may be amorphous or may adopt highly ordered cross-β-sheet structures characteristic of amyloid fibrils.
Colloidal aggregation is governed by colloidal stability theory (DLVO theory), wherein the balance between attractive van der Waals forces and repulsive electrostatic double-layer forces determines aggregation propensity. Peptides formulated near their isoelectric point (pI), where net charge is minimized, typically exhibit maximum aggregation rates due to reduced electrostatic repulsion.
Precipitation¶
Precipitation represents the formation of a macroscopic insoluble phase, typically resulting from exceeding the solubility limit or from chemical modification that reduces solubility. Common triggers include pH shift toward the pI, addition of counterions that form insoluble salts, temperature changes that alter solubility, and chemical degradation that introduces less soluble species.
Surface Adsorption¶
Peptide adsorption to container-closure surfaces (glass, plastic, rubber stoppers) and delivery device components is a significant but often underappreciated stability concern. Adsorption can reduce the effective dose delivered to patients, particularly for low-concentration formulations. The mechanism involves non-specific hydrophobic and electrostatic interactions between the peptide and the surface. Hydrophobic peptides and those with net charge complementary to the surface charge adsorb most strongly. Surfactants (polysorbates) and competitive adsorbents (albumin) are commonly employed to mitigate surface adsorption.
Arrhenius Kinetics and Stability Prediction¶
The Arrhenius equation provides the theoretical foundation for accelerated stability prediction:
k = A · exp(−Ea/RT)
where k is the degradation rate constant, A is the pre-exponential factor, Ea is the activation energy (J/mol), R is the gas constant (8.314 J/mol·K), and T is the absolute temperature (K).
By measuring degradation rates at multiple elevated temperatures (typically 40°C, 50°C, and 60°C), the activation energy can be determined from the slope of an Arrhenius plot (ln k vs. 1/T). Extrapolation to the intended storage temperature (typically 5°C or 25°C) then yields the predicted degradation rate under real-time conditions.
The Arrhenius approach assumes that the degradation mechanism remains unchanged across the temperature range studied. This assumption must be verified by demonstrating that degradation product profiles are qualitatively similar at all temperatures. For peptides, mechanism changes are common — for example, deamidation may predominate at higher temperatures while oxidation dominates at lower temperatures — and uncritical application of Arrhenius extrapolation can lead to grossly inaccurate shelf-life predictions.
The modified Arrhenius equation:
ln k = ln A − Ea/RT + B·RH
incorporates humidity dependence (RH = relative humidity) for lyophilized products where moisture-driven degradation pathways are significant.
Forced Degradation Studies¶
Forced degradation studies (also termed stress testing) are conducted during formulation development to systematically probe the intrinsic stability liabilities of a peptide. These studies deliberately subject the peptide to exaggerated conditions to identify degradation pathways, assess analytical method specificity, and guide formulation strategy.
Standard forced degradation conditions include:
- Thermal stress: Exposure to elevated temperatures (50–80°C) in solid state or solution
- Hydrolytic stress: Exposure to acidic (0.1–1 N HCl) and alkaline (0.1–1 N NaOH) conditions
- Oxidative stress: Treatment with hydrogen peroxide (0.1–3%) or AIBN (radical initiator)
- Photolytic stress: Exposure to UV-visible light per ICH Q1B guidelines (visible: ≥1.2 million lux-hours; UV: ≥200 watt-hours/m²)
- pH stress: Assessment across a pH range (typically pH 2–10) to map the pH-stability profile
- Mechanical stress: Vortexing, shaking, or freeze-thaw cycling to evaluate physical stability
Mass balance assessment (accounting for all degradation products relative to parent loss) is a critical quality metric for forced degradation studies. A mass balance of 95–105% indicates that the analytical method detects all significant degradation products.
ICH Q1A Stability Testing Framework¶
ICH Q1A(R2) establishes the core stability testing requirements for drug substances and drug products. For peptide pharmaceuticals, the typical testing framework includes:
Long-term (real-time) stability: Storage at the intended long-term storage condition (typically 5°C ± 3°C for refrigerated products or −20°C ± 5°C for frozen products) for the proposed shelf-life duration, with testing at defined intervals (0, 3, 6, 9, 12, 18, 24 months, then annually).
Intermediate stability: Storage at 25°C ± 2°C / 60% RH ± 5% for products intended for refrigerated storage, providing data on excursions from the labeled storage condition.
Accelerated stability: Storage at 25°C ± 2°C / 60% RH ± 5% for products intended for refrigerated storage (or 40°C ± 2°C / 75% RH ± 5% for products intended for room-temperature storage), typically over 6 months, to provide early indication of degradation trends.
Stress testing: Performed on a single batch to identify degradation products and validate stability-indicating analytical methods.
Testing attributes typically include appearance, pH, purity and related substances (by HPLC), peptide content (assay), moisture content (for lyophilized products), particulate matter, sterility (for parenteral products), and biological activity (potency). For peptide products specifically, additional tests may include higher-order structure assessment, aggregation (by SEC, DLS, or AUC), and chemical modification profiling (deamidation, oxidation by LC-MS).
Research Evidence¶
The scientific literature provides extensive characterization of peptide degradation kinetics and mechanisms under pharmaceutically relevant conditions.
| Degradation Pathway | Key Residues Affected | Primary Rate Determinants | Detection Methods |
|---|---|---|---|
| Deamidation | Asn, Gln | n+1 residue identity, pH, temperature, buffer | IEX-HPLC, LC-MS, isoAsp detection |
| Oxidation | Met, Cys, Trp, His | Solvent exposure, metal ions, light, peroxide | RP-HPLC, LC-MS, fluorescence |
| Hydrolysis | Asp-Pro, Asp-Gly | pH, temperature, sequence | RP-HPLC, SEC, LC-MS |
| β-Elimination | Cys, cystine | pH (>7), temperature, base | RP-HPLC, free thiol assay |
| Racemization | Asp, Ser | pH (>7), temperature, time | Chiral HPLC, enzymatic assay |
| Aggregation | Hydrophobic regions | Concentration, pH (near pI), temperature, ionic strength | SEC, DLS, AUC, ThT fluorescence |
| Adsorption | Hydrophobic/charged residues | Surface type, peptide concentration, ionic strength | RP-HPLC, ELISA, radiolabeling |
Comprehensive forced degradation studies have been published characterizing the stability profiles of clinically important peptide therapeutics. For example, detailed degradation mapping of insulin analogs has identified deamidation at Asn^A21^ as a primary degradation pathway, with desamido-insulin being the principal degradation product observed during long-term storage. For GLP-1 receptor agonists, oxidation of methionine residues and aggregation have been identified as the primary stability challenges, with formulation pH and excipient selection critically influencing degradation rates.
The development of high-resolution mass spectrometry and advanced chromatographic techniques has dramatically improved the ability to characterize low-abundance degradation products and elucidate complex degradation networks. Multi-attribute method (MAM) approaches, which couple LC-MS with automated data processing, now enable simultaneous monitoring of multiple degradation pathways in a single analysis, substantially improving the efficiency of stability testing.
Current Understanding¶
Contemporary understanding of peptide formulation stability recognizes the interconnected nature of degradation pathways. Chemical modifications such as deamidation and oxidation can alter peptide conformation, exposing hydrophobic surfaces that promote aggregation. Conversely, aggregated peptides may exhibit altered chemical reactivity due to changes in microenvironment and solvent accessibility.
The formulation development paradigm has shifted from empirical stability screening toward mechanism-based design. By understanding the specific degradation liabilities of each peptide sequence, formulators can rationally select pH conditions, buffer species, excipients, and packaging that minimize the most significant degradation pathways. Computational approaches, including molecular dynamics simulations and machine learning models trained on stability datasets, are increasingly employed to predict degradation hotspots and guide formulation optimization.
Stability-indicating analytical methods have matured significantly. The combination of reversed-phase HPLC for purity assessment, size-exclusion chromatography for aggregation monitoring, ion-exchange chromatography for charge variant analysis, and LC-MS for identification of chemical modifications provides a comprehensive analytical toolkit for stability characterization.
Future Research Directions¶
- Predictive stability modeling: Development of machine learning algorithms trained on peptide sequence-stability datasets to predict degradation liabilities and shelf-life from primary structure alone
- Real-time stability monitoring: Integration of process analytical technology (PAT) sensors into formulation development to enable continuous, non-destructive stability assessment
- Multi-attribute method (MAM) advancement: Refinement of LC-MS-based MAM approaches for simultaneous monitoring of all critical quality attributes in a single analysis
- Excipient-mediated stability enhancement: Rational design of novel excipients that preferentially stabilize specific degradation hotspots through computational docking-guided selection
- Container-closure innovation: Development of surface-modified container materials that eliminate peptide adsorption without surfactant addition
- In-use stability standardization: Establishment of harmonized regulatory expectations for in-use stability testing of multi-dose peptide formulations
- Temperature excursion modeling: Creation of validated models to predict product stability following inadvertent temperature excursions during distribution
- Aggregation prediction from sequence: Development of computational tools to predict aggregation propensity directly from amino acid sequence, enabling proactive formulation design
Frequently Asked Questions¶
Why are peptides inherently less stable than small-molecule drugs?
Peptides contain multiple chemically reactive functional groups — amide bonds, amino acid side chains with diverse reactivity, and chiral centers — within a single molecule. Unlike small-molecule drugs that may have a single degradation pathway, each peptide residue represents a potential degradation site. The polymeric nature of peptides also enables physical degradation through conformational changes and aggregation, pathways that are largely absent for small molecules. Furthermore, peptides exist in a delicate thermodynamic balance between folded and unfolded states, and even minor perturbations in formulation conditions can shift this equilibrium toward degradation-prone conformations.
What are the most important degradation pathways to monitor during peptide stability studies?
The critical degradation pathways depend on the peptide's amino acid composition and sequence. As a general framework: (1) Deamidation should be monitored for all Asn- and Gln-containing peptides, particularly at Asn-Gly and Asn-Ser motifs; (2) Oxidation should be assessed for Met- and Cys-containing peptides; (3) Aggregation must be evaluated for all peptide formulations, especially those at high concentration or formulated near the isoelectric point; (4) Hydrolysis should be investigated for peptides containing Asp-Pro or Asp-Gly bonds; (5) Disulfide scrambling must be characterized for disulfide-containing peptides. A comprehensive forced degradation study early in development is essential for identifying the peptide's specific degradation fingerprint. Refer to the analytical guidelines available through the RPL Peptide Research Database for method development support.
How is the Arrhenius equation used to predict peptide shelf-life?
The Arrhenius equation (k = A·e^−Ea/RT^) describes the temperature dependence of reaction rates. In practice, degradation rate constants are determined at several elevated temperatures (e.g., 40°C, 50°C, 60°C). Plotting ln(k) versus 1/T yields a linear relationship with slope −Ea/R. Extrapolation to the intended storage temperature (e.g., 5°C) provides the predicted rate constant under real-time conditions. The shelf-life is then calculated as the time required for a critical quality attribute (typically purity or potency) to reach its acceptance criterion. However, this approach requires validation that the degradation mechanism is identical across the temperature range — a critical assumption that must be experimentally verified for each peptide.
What conditions are recommended for forced degradation studies of peptide formulations?
ICH Q1A(R2) recommends stress testing at conditions that exaggerate the intended storage environment. For peptides in solution: thermal stress (50–80°C for 1–14 days), acid hydrolysis (0.1–1 N HCl, 25–80°C), base hydrolysis (0.1–1 N NaOH, 25–80°C), oxidation (0.1–3% H₂O₂, 25–37°C), and photolysis (ICH Q1B conditions). For lyophilized peptides, thermal stress on the solid is performed at elevated temperatures (60–80°C). The target degradation is 5–20% of the parent peptide — sufficient to reveal major degradation pathways without excessive degradation that complicates mass balance. The specific stress conditions should be tailored to the peptide's expected stability profile; excessively harsh conditions may produce degradation products irrelevant to normal storage.
What is the difference between real-time, intermediate, and accelerated stability testing?
Real-time (long-term) stability testing is conducted at the intended storage condition (e.g., 5°C for refrigerated products) for the full proposed shelf-life and provides the primary data supporting shelf-life assignment. Intermediate stability testing is performed at 25°C/60% RH and addresses the effect of temporary temperature excursions above the labeled storage condition. Accelerated stability testing at 25°C or 40°C provides early data on degradation trends and supports formulation screening, but cannot substitute for real-time data in shelf-life determination. For peptide products, the relationship between accelerated and real-time degradation can be complex due to mechanism changes at different temperatures, and regulatory agencies generally expect real-time data to support shelf-life claims.
How does pH influence peptide chemical stability?
Each degradation pathway exhibits a characteristic pH-rate profile. Deamidation typically shows a minimum rate between pH 3.0 and 5.0, with acceleration at both acidic and basic pH. Oxidation is generally faster at neutral to alkaline pH. Asp-Pro hydrolysis is fastest at acidic pH (2–4). β-Elimination requires alkaline conditions. Aggregation is fastest near the peptide's isoelectric point. The optimal formulation pH thus represents a compromise that minimizes the sum of all significant degradation pathways. Complete pH-rate profiling across pH 2–10 is an essential component of formulation development and is recommended as a standard practice for all peptide candidates. For specific guidance, consult the formulation resources at RPL Peptide.
What analytical methods are essential for peptide stability assessment?
A comprehensive stability-indicating analytical panel typically includes: (1) Reversed-phase HPLC for purity/related substances; (2) Size-exclusion chromatography (SEC) for soluble aggregates; (3) Ion-exchange HPLC for charge variants (deamidation products); (4) LC-MS for identification of chemical modifications; (5) Dynamic light scattering (DLS) for subvisible particle characterization; (6) Appearance and visible particulate assessment; (7) pH measurement; (8) Peptide content (assay); (9) Biological activity (potency) by cell-based assay or receptor binding; and (10) Residual moisture (Karl Fischer) for lyophilized products. Method validation per ICH Q2(R1) is required for all stability-indicating methods used in regulatory submissions.
How are stability specifications established for peptide drug products?
Stability specifications define the acceptable limits for quality attributes throughout shelf-life. They are established based on: (1) Data from formal stability studies on primary (registration) batches; (2) Knowledge of degradation rates and their impact on safety and efficacy; (3) The capability of the manufacturing process; (4) Regulatory guidance (ICH Q6B for biotechnological products). For peptide products, typical specifications include: purity ≥95% (individual impurity ≤2.0%, total impurities ≤5.0%), assay 90.0–110.0% of label claim, pH within ±0.5 units of target, and potency 80–125% of label claim. Specifications may be tightened at shelf-life based on stability data and clinical experience.
What are the special stability considerations for lyophilized peptide products?
Lyophilized peptide products present unique stability considerations: (1) Residual moisture is a critical quality attribute — typically 1–3% maximum — as water plasticizes the glassy matrix, reducing glass transition temperature and accelerating degradation; (2) The amorphous solid-state environment may alter degradation mechanisms compared to solution; (3) Cake appearance (color, shrinkage, collapse) provides qualitative stability information; (4) Reconstitution time and completeness must be monitored; (5) Headspace oxygen and moisture ingress through stopper closure must be controlled. Lyophilized products typically exhibit substantially longer shelf-lives than solution formulations but require careful characterization of the solid-state degradation profile.
How should photo-stability of peptide formulations be evaluated?
Photo-stability evaluation follows ICH Q1B guidelines. Peptide drug substances and products should be exposed to a combination of visible light (≥1.2 million lux-hours) and near-ultraviolet light (≥200 watt-hours/m²). Testing should include: (1) Fully exposed samples; (2) Samples in immediate (primary) packaging; (3) Samples in marketing (secondary) packaging if the product is photosensitive. A dark control should be included to distinguish photolytic from thermal degradation. Photo-stability assessment is particularly important for peptides containing tryptophan, tyrosine, phenylalanine, and disulfide bonds, which absorb UV radiation and are susceptible to photochemical degradation.
References¶
- ICH Harmonised Tripartite Guideline. Stability Testing of New Drug Substances and Products Q1A(R2). International Conference on Harmonisation. 2003. ICH Q1A(R2)
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
- Patel K, Borchardt RT. Chemical pathways of peptide degradation. II. Kinetics of deamidation of an asparaginyl residue in a model hexapeptide. Pharm Res. 1990;7(7):703-711. doi:10.1023/A:1015807303767
- Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. 1995;48(5):490-500. doi:10.1002/bit.260480511
- Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides: succinimide-linked reactions that contribute to protein degradation. J Biol Chem. 1987;262(2):785-794. doi:10.1016/S0021-9258(19)75855-4
- Waterman KC, Adami RC. Accelerated aging: prediction of chemical stability of pharmaceuticals. Int J Pharm. 2005;293(1-2):101-125. doi:10.1016/j.ijpharm.2004.12.013
- Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst. 1993;10(4):307-377. PMID: 8124729
- Nguyen TH, Burnier J, Meng W. The kinetics of relaxin oxidation by hydrogen peroxide. Pharm Res. 1993;10(11):1563-1571. doi:10.1023/A:1018908316460
- Brange J, Langkjær L, Havelund S, Vølund A. Chemical stability of insulin. 1. Hydrolytic degradation during storage of pharmaceutical preparations. Pharm Res. 1992;9(6):715-726. doi:10.1023/A:1015835017916
- Volkin DB, Mach H, Middaugh CR. Degradative covalent reactions important to protein stability. Mol Biotechnol. 1997;8(2):105-122. doi:10.1007/BF02752255
- Wakankar AA, Borchardt RT. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. J Pharm Sci. 2006;95(11):2321-2336. doi:10.1002/jps.20740
- Wei W, Huddleston MJ, Marshall AG. Observation of acidic peptides eluting as a single peak with mixed-mode HPLC-MS. Anal Chem. 2002;74(13):3156-3163. doi:10.1021/ac015707i
- ICH Harmonised Tripartite Guideline. Stability Testing: Photostability Testing of New Drug Substances and Products Q1B. International Conference on Harmonisation. 1996. ICH Q1B
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185(2):129-188. doi:10.1016/S0378-5173(99)00152-0
- Byrn SR, Xu W, Newman AW. Chemical reactivity in solid-state pharmaceuticals: formulation implications. Adv Drug Deliv Rev. 2001;48(1):115-136. doi:10.1016/S0169-409X(01)00102-8
This article is for educational and research information purposes only. For peptide stability testing services and analytical support, visit RPL Peptide and the RPL Peptide Research Database.